Search for:
Category

Hungary

Category

In brief The National Institute of Pharmacy and Nutrition (“OGYÉI”) has issued new decisions on its webpage concerning pharmaceutical promotional activities and interactions with HCPs in which the commercial practices of two pharmaceutical companies were investigated and fines were imposed due to alleged infringements. The key findings of the decisions…

The National Institute of Pharmacy and Nutrition (“OGYÉI”) published new decisions on its webpage concerning pharmaceutical promotional activities and interactions with HCPs. The OGYÉI investigated the commercial practices of Aramis Pharma Kft., Lilly Hungária Kft. and Sager Pharma Kft. and imposed fines due to alleged infringements.

The financial markets are experiencing a significant amount of disruption for which there is no precedent. However, in these difficult times it is important that originators, sponsors and securitisation special purpose entities (SSPEs) do not lose sight of their regulatory obligations under Regulation (EU) 2017/2402 (Securitisation Regulation). This short briefing…